DuPont ™ Liveo™ for Healthcare Silicone Solutions Is Introduced

DuPont is a globally recognized leader in silicone-based technology with more than 70 years of experience advancing healthcare through materials innovation, is introducing DuPont Liveo, a new brand name for its extensive range of silicone healthcare solutions. The news was announced today.

Inspired by the terms “live” and “to be alive,” the new Liveo brand name reflects DuPont Healthcare’s drive to create next-generation, innovative solutions that can help patients live life to the fullest.

“As the new name for the longest legacy in healthcare applied silicones brought by DOW CORNING, Liveo stands for smarter healthcare and positive patient outcomes,” says DuPont Liveo Healthcare Global Marketing Manager Jennifer Gemo Mathis.

More than a name change, the Liveo brand reinforces DuPont’s commitment in healthcare and renewed energy to build on more than 70 years of innovation development capabilities, regulatory and manufacturing know-how, and application expertise.

Historically marketed with a DOW CORNING or SILASTIC trade name, the product offering and packaging material are not changing, and all locations will continue to manufacture the same products, using the same rigorous processes and quality oversight as before. Looking ahead, the Liveo brand will reinforce DuPont’s competitive advantages and leadership positions in three key healthcare markets – Biopharmaceutical Processing, Pharmaceutical Solutions and Medical Devices.

“We are making significant investments in both capital and resources to strengthen our strategic capabilities to support our customers’ leadership in key healthcare industry market segments, and we are particularly proud of the contribution that our teams and products have provided to our customers without disruptions during the COVID-19 pandemic outbreak,” says DuPont Liveo Healthcare Global Business Director Eugenio Toccalino.

The Liveo brand product line includes pharma tubing and overmolded assemblies for single-use systems in biopharma processing, transdermal and topical drug delivery systems, medical adhesives for advanced wound care and ostomy care and wearables, silicone elastomers for a wide range of specialty medical devices, anti-flatulent active pharmaceutical ingredients, silicone antifoams, coating, fluids, emulsions and much more. The Liveo product line continues to be manufactured at the DuPont Healthcare Industries Materials Site (HIMS) in Hemlock, Michigan, USA, which is an ISO 9001:2015 and ISO 14000 registered site and FDA registered utilizing GMPs.

 

SourceDupont

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version